The BENEDICT study, carried out on patients with type 2 diabetes and hypertension, investigated the effectiveness of the ACE-inhibitor trandolapril as compared to the non-dihydropyridine calcium channel blocker verapamil given alone or in combination, over a mean 3.6 year follow-up period [64]. The gene discussed is ACE; the disease is type 2 diabetes mellitus.